Skip to main content
. 2013 Aug 18;2013:915873. doi: 10.1155/2013/915873

Figure 1.

Figure 1

BM Th17 and Th1 cells in representative patients with ND, CR, and relapsed-refractory AML and controls. (a) 5000 CD4+ cells were collected by flow cytometry. (b) CD4+ lymphocytes were gated. (c), (d), (e), and (f) The percentages of BM Th17 (CD4+ IL-17+) cells in ND, CR, and relapsed-refractory AML patients and controls. (g), (h), (i), and (j) The percentages of BM Th1 (CD4+ IFN-γ +) cells in ND, CR, and relapsed-refractory AML patients and controls.